Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Hematology Am Soc Hematol Educ Program, 2010, 95(1): 8-12.
[3]
Score J, Calasanz MJ, Ottman O, et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation[J]. Leukemia, 2010, 24(10): 1742-1750.
[4]
Mizuta S, Matsuo K, Maeda T, et al. Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL[J]. Blood Cancer J, 2012, 2(5): e72.
[5]
Ohno R. Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Curr Hematol Malig Rep, 2010, 5(4): 213-221.
[6]
[ 1 ] Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there[J]. Blood, 2012, 120(6): 1165-1174.
[7]
[ 2 ] American Cancer Society. Cancer Facts and Figures 2014[R]. Atlanta, Ga: American Cancer Society, 2014.
[8]
[ 3 ] Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hea matopoietic and lymphoid tissues[M]. 4 ed. Lyon: LARC Press, 2008: 168-178.
[9]
[ 4 ] Shahnazi M, Khatami A, Shamsian B, et al. Bony lesions in pediatric acute leukemia: pictorial essay[J]. Iran J Radiol, 2012, 9(1): 50-56.
[10]
[ 5 ] Bertuna G, Famà P, Lo Nigro L, et al. Marked osteoporosis and spontaneous vertebral fractures in children: don’t forget, it could be leukemia[J]. Med Pediatr Oncol, 2003, 41(5): 450-451.
[11]
[ 6 ] Atas A, Cakmak A, Soran M, et al. Severe osteoporosis and high level TSH in a child before the diagnosis of acute lymphoblastic leukemia[J]. Pediatr Hematol Oncol, 2009, 31(8): 588-591.
[12]
[ 7 ] Hafiz MG, Islam A. Extensive skeletal lesions in childhood acute lymphoblastic leukemia[J]. Mymensingh Med J, 2009, 18(1): 88-94.
[13]
[ 8 ] Hafiz MG, Islam A, Siddique R. Back pain and vertebral compression:an unusu al presentation of childhood acute lymphoblastic leukemia[J]. Mymensingh Med J, 2010, 19(1): 130-136.
Dimou M, Panayiotidis P. Tyrosine kinase inhibitors and interferon[J]. Mediterr J Hematol Infect Dis, 2014, 6(1): e2014006.
[18]
Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study[J]. Blood, 2008, 111(8): 4022-4028.
